Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13915061 | 0.95 | ADK (0.31) | ADK | |
| SCHEMBL13906800 | 0.90 | RIPK2 (0.32) | ADK | |
| SCHEMBL3946173 | 0.90 | RIPK2 (0.32) | ADK | |
| SCHEMBL3959198 | 0.89 | CCNT1 (0.31) | — | |
| SCHEMBL13906778 | 0.89 | CCNT1 (0.31) | — | |
| SCHEMBL13906779 | 0.85 | CCNT1 (0.30) | — | |
| SCHEMBL3957319 | 0.85 | LMNA (0.30) | — | |
| SCHEMBL13905109 | 0.85 | LMNA (0.30) | — | |
| SCHEMBL3953317 | 0.85 | CCNT1 (0.30) | — | |
| SCHEMBL3946746 | 0.82 | ADORA2A (0.38) | ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062223-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062223-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | PNP, SLC29A1, SLC28A1 | ADK 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.